ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO1165

Incidence and Long-Term Outcomes of Neonatal Renal Vein Thrombosis in Ontario: A Population-Based Cohort Study

Session Information

  • Pediatric Nephrology - I
    October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pediatric Nephrology

  • 1600 Pediatric Nephrology


  • Ouellette, Allison C., McMaster University, Hamilton, Ontario, Canada
  • Darling, Liz, McMaster University, Hamilton, Ontario, Canada
  • Babe, Glenda, Institute for Clinical and Evaluative Sciences, Hamilton, Ontario, Canada
  • Perez, Richard, ICES, Hamilton, Cabo Verde
  • Chan, Anthony K c, McMaster University, Hamilton, Ontario, Canada
  • Chanchlani, Rahul, McMaster University, Hamilton, Ontario, Canada

There is limited data at a population level on the burden and long-term outcomes of neonatal renal vein thrombosis (nRVT). We conducted a cohort study to determine the incidence and long-term outcomes including hypertension (HTN), chronic kidney disease (CKD), end-stage renal disease (ESRD) and mortality associated with nRVT during a period of 24 years.


Health administrative databases, housed at the Institute for Clinical Evaluative Sciences, were used to identify all neonates ≤28 days of age born in Ontario, Canada from 1992-2016 and compared all neonates with nRVT vs. the total neonatal population without nRVT. The primary outcome was the composite risk of long-term outcomes including CKD, ESRD (chronic dialysis or kidney transplant) and all-cause mortality. The secondary outcome was the long-term risk of HTN. Incidence rates (IR) were calculated and Cox proportional hazard models were fitted for all outcomes.


The annual IR of nRVT in Ontario from 1992-2016 was 2.6 per 100,000 live births (total 85 cases from 3,001,637 live births). The median follow-up was 11 years in both cohorts. There was a male preponderance (64%) of nRVT. A greater proportion of nRVT vs. comparator cohort was premature (45% vs. 8%, Standardized Difference 0.92). After adjusting for confounders, patients with nRVT were at a 17-fold increased risk of CKD or death (Hazard Ratio (HR) 16.9, 95% CI 12.3-23.2, p<.0001) and an 18-fold increased risk of HTN (HR 17.7, 95% CI 12.6-25.0, p<.0001) vs. the comparator cohort. None of the nRVT cohort developed ESRD.


Patients with nRVT remain at higher risk than the general neonatal population of long-tern morbidity and mortality, indicating the need for long-term follow-up.

Table 1: Incident rates and hazard ratios of adverse outcomes among patients with nRVT in Ontario from 1992-2016
OutcomesProportion of live births with outcomeRisk of adverse outcomes
nRVT Cohort n=85Comparator Cohort n=3,001,552Unadjusted HR95% CI†Adjusted HR*95% CI†
Primary OutcomeCKD or Death43%0.7%67.649.4 - 92.516.912.3 - 23.2
Secondary OutcomeHTN39%2%30.021.3 - 42.217.712.6 - 25.0

† All outcomes were significant with p<0.0001 *Adjusted for sex, congenital heart disease, respiratory distress syndrome, sepsis, maternal preeclampsia or eclampsia, and maternal diabetes. CKD, chronic kidney disease; HTN, hypertension; HR, hazard ratio; CI, confidence interval.